Non-Small Cell Lung Cancer Market Size, Trends Analysis, 2032

Non-Small Cell Lung Cancer Market: Industry Perspective

The global non-small cell lung cancer market size was worth around USD 19.56 Billion in 2023 and is predicted to grow to around USD 43.48 Billion by 2032 with a compound annual growth rate (CAGR) of roughly 9.28% between 2024 and 2032. The report analyzes the global non-small cell lung cancer market's drivers, restraints/challenges, and the effect they have on the demands during the projection period. In addition, the report explores emerging opportunities in the non-small cell lung cancer industry.

Request Free Sample

Non-Small Cell Lung Cancer Market: Overview

Lung cancer is categorized as non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) in two forms. Lung cancer is uncontrolled lung tissue cell growth. Lung cancer's bulk is NSCLC. Common symptoms include chest pain, wheezing, blood vomiting, heaviness, weight loss, persistent bronchitis, loss of appetite, tiredness, shortness of breath, bone pain, trouble swallowing, and limb numbness. Increasing incidences of smoking-related lung cancer, air pollution (asbestos, cadmium, and radon), HIV infection, and population growth are a few of NSCLC's growth factors.

Non-Small Cell Lung Cancer Market: Segmentation Analysis

The study provides a decisive view of the Non-Small Cell Lung Cancer market by segmenting the market based on Type, Therapy, Distribution Channel and regions. All the segments have been analyzed based on present and future trends and the market is estimated from 2024 to 2032.

Based on Type, the market is segmented into Squamous cell (epidermoid) carcinoma, Adenocarcinoma, Large cell (undifferentiated) carcinoma and Others. In any section of the lung, large cell carcinoma or its undifferentiated form develops, rises fastest and is difficult to treat. Adenocarcinoma is the slowest growth compared to two other types and is found in the outer lung cells responsible for mucous secretion.

Based on the Therapy segment, the market is bifurcated into Chemotherapy, Radiotherapy, Laser therapy, Photodynamic therapy (PDT) and Others.  

Based on the Distribution Channel segment, the market is bifurcated into Hospital pharmacies, Online pharmacies and Others. The distribution channel group for hospital pharmacies will have a significant share over the coming years. Hospital pharmacies typically store a large number of drugs and advanced equipment and provide hospital patients with medication. The burden of genetic disorders would increase the number of hospitalizations, thereby having a positive effect on hospital pharmaceutical development.

Non-Small Cell Lung Cancer Market: Regional Analysis

The geographical segmentation comprises the current and forecast demand for North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. It is expected that North America will have the largest market share in the forecast period followed by Europe. It can also be predicted to be a significant contributor to the NSCLC market due to increased smoking habits in developing countries in the Asia Pacific region.

Increasing incidences of lung cancer associated with smoking, air pollution (asbestos, cadmium, and radon), HIV infection, and population growth are just a few of the growth factors of NSCLC.

Non-Small Cell Lung Cancer Market: Report Scope

Non-Small Cell Lung Cancer Market: Competitive Analysis

Some of the major players in the global non-small cell lung cancer market include:

• Agennix AG
• AstraZeneca
• Eli Lily
• GlaxoSmithKline
• Merck & Co.
• Novartis AG
• Pfizer
• Roche

The global non-small cell lung cancer market is segmented as follows;

Global Non-Small Cell Lung Cancer Market: Type Segment Analysis

• Squamous cell (epidermoid) carcinoma
• Adenocarcinoma
• Large cell (undifferentiated) carcinoma
• Other

Global Non-Small Cell Lung Cancer Market: Therapy Segment Analysis

• Chemotherapy
• Radiotherapy
• Laser therapy
• Photodynamic therapy (PDT)
• Others

Global Non-Small Cell Lung Cancer Market: Distribution Channel Segment Analysis

• Hospital pharmacies
• Online pharmacies
• Others

 Global Non-Small Cell Lung Cancer Market: Regional Segment Analysis

• North America
  • U.S.
• Europe
  • UK
  • France
  • Germany
• Asia Pacific
  • China
  • Japan
  • India
• Latin America
  • Brazil
• Middle East and Africa